Molecular and genetic characterization of sarcospan: insights into sarcoglycan–sarcospan interactions

RH Crosbie, LE Lim, SA Moore, M Hirano… - Human molecular …, 2000 - academic.oup.com
RH Crosbie, LE Lim, SA Moore, M Hirano, AP Hays, SW Maybaum, H Collin, SA Dovico…
Human molecular genetics, 2000academic.oup.com
Autosomal recessive limb girdle muscular dystrophies 2C–2F represent a family of diseases
caused by primary mutations in the sarcoglycan genes. We show that sarcospan, a novel
tetraspan-like protein, is also lost in patients with either a complete or partial loss of the
sarcoglycans. In particular, sarcospan was absent in a γ-sarcoglycanopathy patient with
normal levels of α-, β-and δ-sarcoglycan. Thus, it is likely that assembly of the complete,
tetrameric sarcoglycan complex is a prerequisite for membrane targeting and localization of …
Abstract
Autosomal recessive limb girdle muscular dystrophies 2C–2F represent a family of diseases caused by primary mutations in the sarcoglycan genes. We show that sarcospan, a novel tetraspan-like protein, is also lost in patients with either a complete or partial loss of the sarcoglycans. In particular, sarcospan was absent in a γ-sarcoglycanopathy patient with normal levels of α-, β- and δ-sarcoglycan. Thus, it is likely that assembly of the complete, tetrameric sarcoglycan complex is a prerequisite for membrane targeting and localization of sarcospan. Based on our findings that sarcospan is integrally associated with the sarcoglycans, we screened >50 autosomal recessive muscular dystrophy cases for mutations in sarcospan. Although we identified three intragenic polymorphisms, we did not find any cases of muscular dystrophy associated with primary mutations in the sarcospan gene. Finally, we have identified an important case of limb girdle muscular dystrophy and cardiomyopathy with normal expression of sarcospan. This patient has a primary mutation in the γ‐sarcoglycan gene, which causes premature truncation of γ-sarcoglycan without affecting assembly of the mutant γ-sarcoglycan into a complex with α-, β‐ and δ-sarcoglycan and sarcospan. This is the first demonstration that membrane expression of a mutant sarcoglycan–sarcospan complex is insufficient in preventing muscular dystrophy and cardiomyopathy and that the C-terminus of γ-sarcoglycan is critical for the functioning of the entire sarcoglycan–sarcospan complex. These findings are important as they contribute to a greater understanding of the structural determinants required for proper sarcoglycan–sarcospan expression and function.
Oxford University Press